Search
OncoCyte Corp
OCXAdd to Watchlist
3.200USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
91.52MMarket Cap
LossP/E TTM
More Details of OncoCyte Corp Company
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.
OncoCyte Corp Info
Ticker SymbolOCX
Company nameOncoCyte Corp
IPO dateDec 30, 2015
CEOMr. Joshua Riggs
Number of employees46
Security typeOrdinary Share
Fiscal year-endDec 30
Address15 Cushing
CityIRVINE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92618
Phone19494097600
Websitehttps://oncocyte.com/
Ticker SymbolOCX
IPO dateDec 30, 2015
CEOMr. Joshua Riggs
Company Executives of OncoCyte Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew (Andy) Arno
Mr. Andrew (Andy) Arno
Chairman of the Board
Chairman of the Board
152.16K
+0.04%
Dr. Andrew J. Last
Dr. Andrew J. Last
Independent Director
Independent Director
39.51K
+1.96%
Mr. Louis E. (Lou) Silverman
Mr. Louis E. (Lou) Silverman
Independent Director
Independent Director
36.56K
+6.12%
Mr. Joshua Riggs
Mr. Joshua Riggs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.50K
--
Mr. James Liu, CPA
Mr. James Liu, CPA
Principal Accounting Officer, Vice President - Accounting, Controller, Treasurer
Principal Accounting Officer, Vice President - Accounting, Controller, Treasurer
--
--
Dr. Ekkehard Schuetz, M.D., Ph.D.
Dr. Ekkehard Schuetz, M.D., Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Ms. Andrea S. James
Ms. Andrea S. James
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew (Andy) Arno
Mr. Andrew (Andy) Arno
Chairman of the Board
Chairman of the Board
152.16K
+0.04%
Dr. Andrew J. Last
Dr. Andrew J. Last
Independent Director
Independent Director
39.51K
+1.96%
Mr. Louis E. (Lou) Silverman
Mr. Louis E. (Lou) Silverman
Independent Director
Independent Director
36.56K
+6.12%
Mr. Joshua Riggs
Mr. Joshua Riggs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.50K
--
Mr. James Liu, CPA
Mr. James Liu, CPA
Principal Accounting Officer, Vice President - Accounting, Controller, Treasurer
Principal Accounting Officer, Vice President - Accounting, Controller, Treasurer
--
--
Dr. Ekkehard Schuetz, M.D., Ph.D.
Dr. Ekkehard Schuetz, M.D., Ph.D.
Chief Science Officer
Chief Science Officer
--
--
FAQs
Who are the top five shareholders of OncoCyte Corp?
The top five shareholders of OncoCyte Corp are: Mr. Andrew (Andy) Arno
How many institutions hold shares of OncoCyte Corp (OCX)?
As of 2026Q1, 71 institutions hold shares of OncoCyte Corp, with a combined market value of approximately 18.24M, accounting for 55.57% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1766727.00.
What is the biggest source of revenue for OncoCyte Corp?
In 2026Q1, the Pharma Services business generated the highest revenue for OncoCyte Corp, amounting to 4.01M and accounting for 99.00% of total revenue.